Skip to main content
. 2006 May 10;8(2):36.

Figure 2.

Figure 2

Percentage of patients treated with either saquinavir-soft gelatin capsule/ritonavir or efavirenz both once-daily in combination with 2 nucleoside reverse transcriptase inhibitors, with undetectable HIV-RNA levels (< 50 copies/mL), as detected by the Ultra-Sensitive assay.

ITT=intent to treat; OT=on treatment